Rumors of the IPO window's death are greatly exaggerated. Despite a handful of postponed biotech IPOs in the last two weeks, three money managers contacted by BioCentury say the market is merely taking a holiday as investors - in particular generalists - look to minimize risk before year end.

The money managers think the new year should see more IPOs getting done. But they say investors will likely be more selective than they were over the spring and summer.